alopecia areata
Conditions
Interventions
treatment group:Tofacitinib 11mg qd
Sponsors
West China Hospital, Sichuan University
Eligibility
Sex/Gender
All
Age
18 Years to 55 Years
Inclusion criteria
Inclusion criteria: 1) Subjects are between the ages of 18-55 years old, including both males and females; 2) Meet the diagnostic criteria for pemphigus vulgaris; 3) Those who did not receive topical or systemic treatment for the first time before the baseline visit or who have received treatment but it is ineffective, and who are able to comply with the medication prescribed by the doctor and have regular follow-up visits; 4) Blood and urine routine, common evaluation indexes of liver function (alanine aminotransferase, glutamine aminotransferase, alkaline phosphatase and gamma-glutamyl transpeptide, etc.) and common evaluation indexes of renal function (blood creatinine, endogenous creatinine clearance, urea nitrogen, etc.) are within the normal range; 5) No other autoimmune diseases were found; 6) Signed informed consent and picture authorization
Exclusion criteria
Exclusion criteria: 1) Pregnant and lactating women, and men with recent plans to have children; 2) Those with other concurrent alopecia lesions (e.g., androgenetic alopecia, tinea capitis, hair-pulling fetish, etc.); 3) Those who use other drugs that affect the observation of the efficacy of this study before the baseline visit (e.g. use of CYP3A4 inhibitors, etc.); 4) Severe hepatic or renal insufficiency; 5) Active tuberculosis, hepatitis B, syphilis, immunodeficiency virus (HIV) infected subjects, etc.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| SALT; | — |
Secondary
| Measure | Time frame |
|---|---|
| Dermatoscope Pictures; | — |
Countries
China
Contacts
Public ContactYuping Ran
West China Hospital, Sichuan University
Outcome results
None listed